MK0429
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Post-Menopausal Osteoporosis
Conditions
Post-Menopausal Osteoporosis
Trial Timeline
Dec 1, 2000 → Oct 1, 2002
NCT ID
NCT00533650About MK0429
MK0429 is a phase 2 stage product being developed by Merck for Post-Menopausal Osteoporosis. The current trial status is completed. This product is registered under clinical trial identifier NCT00533650. Target conditions include Post-Menopausal Osteoporosis.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00533650 | Phase 2 | Completed |
Competing Products
19 competing products in Post-Menopausal Osteoporosis